Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of everolimus in de novo heart transplant recipients.

Trial Profile

Efficacy and safety of everolimus in de novo heart transplant recipients.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2015

At a glance

  • Drugs Ciclosporin; Everolimus; Mycophenolate mofetil
  • Indications Heart transplant rejection; Renal transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 15 Jul 2009 Primary endpoint 'Creatinine clearance' has not been met; results published in 'Transplantation'.
    • 03 Jun 2009 Results were reported at the American Transplant Congress -- 9th Joint Congress of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top